Last updated: April 23, 2026
Who Supplies Itraconazole to the Pharmaceutical Market?
Itraconazole is a widely distributed small-molecule antifungal. The supplier set spans (1) API manufacturers, (2) finished-dose and intermediate makers, and (3) distribution channels that aggregate finished products and generics.
What supplier categories sell Itraconazole?
1) Itraconazole API (active pharmaceutical ingredient)
Suppliers provide itraconazole API for generic solid oral dosage forms (capsules/tablets) and some compounding markets. Common API commercial structures include:
- Itraconazole API manufactured in bulk and sold to formulators
- API supplied through trading houses that route to dossier-holding generic manufacturers
- Long-term supply arrangements to support ANDA, DMF, CEP, or local registration dossiers
2) Finished dosage manufacturers
Suppliers provide finished products (capsules, tablets, oral solids) under brand or generic registrations:
- Branded originator-channel supply (historically, Janssen and licensees in different territories)
- Generic finished-dose manufacturers in regional markets (Europe, MENA, LatAm, APAC, US)
3) Intermediate and contract manufacturing
Many commercial supply chains use contract manufacturers for:
- Crystallization/polymorph control
- Milling and particle-size adjustments for dissolution performance
- Encapsulation and tabletting lines with validated dissolution specs
Which companies supply itraconazole globally?
API and intermediate suppliers (commercially active)
The following entities are repeatedly present as API or pharma-chemical participants in itraconazole supply networks, through direct manufacturing or dossier-supported supply:
| Supplier |
Type |
Typical role in supply chain |
| Janssen Pharmaceuticals (J&J) |
Branded originator |
Originator supply and licensing history for itraconazole products |
| Sandoz |
Finished-dose and generic portfolio |
Generic manufacturing and market supply in assigned territories |
| Teva |
Finished-dose and generic portfolio |
Generic market supply via regional manufacturing networks |
| Cipla |
Finished-dose and generic portfolio |
Generic market supply for itraconazole oral solids |
| Mylan (Upjohn legacy) |
Finished-dose and generic portfolio |
Generic distribution through branded and generic product programs |
| Aurobindo Pharma |
Finished-dose and generic portfolio |
Generic supply in multiple regulated markets |
| Sun Pharmaceutical Industries |
Finished-dose and generic portfolio |
Generic supply for itraconazole oral solids |
| Dr. Reddy’s Laboratories |
Finished-dose and generic portfolio |
Generic supply through regional manufacturing |
| Torrent Pharmaceuticals |
Finished-dose and generic portfolio |
Generic supply in India and exports |
| Hetero Drugs |
Finished-dose and generic portfolio |
Generic supply for oral antifungals |
| Cadila / Zydus |
Finished-dose and generic portfolio |
Generic supply presence in multiple markets |
Notes on how these firms function in practice: for itraconazole, the largest set of supplier visibility comes from finished-dose registrants because those firms publish product registrations and tend to list manufacturing sites. API manufacturing is often less visible publicly unless a DMF/CEP path is cited in regulatory databases.
Where do itraconazole suppliers sell most volume?
Supply is concentrated in regulated generic markets where dossier approvals drive stable procurement:
- United States: generic submissions and distribution through national wholesalers
- European Union: company-specific batch release and national market procurement
- India and APAC: heavy domestic supply and export-driven manufacturing
- LatAm and MENA: competitive generics with importer-driven distribution models
What do procurement teams verify for itraconazole supply?
Regulatory and quality package
Procurement typically validates:
- API source (manufacturer name tied to DMF or CEP where applicable)
- Sterility is not required (itraconazole is solid oral; sterility comes into play for parenterals, which are not the dominant itraconazole format)
- Manufacturing site compliance to GMP (inspection history and quality agreement)
- Dissolution and bioequivalence performance for finished products (especially between capsule/tablet presentations)
Formulation-relevant parameters
- Particle size and solid-state form impact dissolution rate and in-vivo performance
- Bioequivalence evidence for generics (where required)
- Stability profile under local storage and transport conditions
Supplier landscape by product format
Capsules (dominant legacy format)
Most market supply is capsule-based historically. Supplier set is dominated by:
- Major generic finished-dose players listed above
- Regional manufacturers in regulated and semi-regulated markets
Tablets
Tablet supply is more common in certain regions and varies by portfolio. Procurement often compares:
- Dissolution profile and site-specific performance
- Strengths and excipient sets
Oral solid distribution channels
In practice, global availability is frequently mediated by:
- National distributors (tied to procurement contracts)
- Wholesalers that source from multiple generic manufacturers
What is the “supplier shortlist” structure for itraconazole sourcing?
A typical high-throughput procurement model for itraconazole uses two tiers:
- Tier 1: finished-dose suppliers with active registrations in the target geography
- Tier 2: API/contract manufacturers supplying the chosen dossier-holding finished-dose line
This structure reduces regulatory exposure because finished-dose dossiers anchor ongoing quality documentation, while API sourcing can be swapped only within pre-approved quality change controls.
Key Takeaways
- Itraconazole supply is dominated by finished-dose generic manufacturers with stable regional procurement channels; API sourcing is often less visible but is centrally controlled through dossier-linked quality systems.
- Supplier evaluation focuses on GMP compliance, regulatory dossier linkage, and dissolution/bioequivalence performance for oral solids.
- For commercial sourcing, build a two-tier procurement view: finished-dose supplier (regulatory anchor) and API/contract supply (manufacturing continuity).
FAQs
1) Is itraconazole API sourced differently than sterile injectables?
Yes. Itraconazole is primarily solid oral, so procurement prioritizes solid-state quality, dissolution performance, and GMP for oral solids, not sterility.
2) Which supplier group is most reliable for uninterrupted market supply?
Finished-dose dossier holders with established distribution networks are typically the most reliable for uninterrupted supply because they control validated manufacturing and release.
3) Does the supplier list change by geography?
Yes. Generics in the US, EU, India, and LatAm often differ in which companies hold registrations and who has local distribution contracts.
4) What product attributes drive supplier selection for itraconazole?
Dissolution profile, bioequivalence evidence, strength range, and stability under local conditions drive selection more than marketing claims.
5) Can procurement switch API suppliers mid-contract?
Only within approved quality change controls. In practice, dossier-linked controls often limit API changes unless quality, dissolution, and regulatory requirements are met.
References
[1] Janssen Pharmaceuticals. Clinical and product information for itraconazole. Janssen. (Referenced via company product and licensing history).
[2] U.S. FDA. Drug Approval Reports and bioequivalence-related documentation for itraconazole products. FDA.
[3] European Medicines Agency (EMA). Public assessment and product information for itraconazole-containing medicines. EMA.
[4] World Health Organization. WHO Model List of Essential Medicines: itraconazole (status and listing context). WHO.
[5] DrugBank. Itraconazole (drug profile and commercial background). DrugBank.
